Buspirone Dosing: BID vs TID
Start buspirone at 7.5 mg twice daily (BID) and titrate to 15 mg BID for most patients, as this regimen offers equivalent efficacy to three-times-daily dosing with improved convenience and potentially better adherence. 1
Dosing Algorithm
Initial Dosing
- Start: 7.5 mg BID (15 mg total daily dose) 1
- Alternative: 5 mg TID if BID dosing causes tolerability issues
- Titration: Increase by 5 mg/day every 2-3 days as needed 1
- Target: 15 mg BID (30 mg total daily) for most patients
- Maximum: 60 mg/day (can be given as 30 mg BID or 20 mg TID) 1
Evidence Supporting BID Dosing
The FDA label explicitly recommends starting at 15 mg daily given as 7.5 mg BID, with common therapeutic doses of 20-30 mg/day in divided doses 1. Research directly comparing these regimens found no appreciable difference in efficacy or safety between buspirone 15 mg BID versus 10 mg TID 2, 3. Both regimens produced:
- Equivalent reductions in Hamilton Anxiety Scale scores
- Similar improvements in Clinical Global Impression measures
- Comparable adverse event profiles (except slightly higher palpitations with BID: 5% vs 1%) 3
Special Considerations
Food consistency matters: Buspirone bioavailability increases significantly with food 1. Instruct patients to take it consistently either always with food or always without food to maintain stable drug levels.
Drug interactions requiring dose adjustment:
- With strong CYP3A4 inhibitors (itraconazole, nefazodone, erythromycin): Start at 2.5 mg BID or even 2.5 mg once daily 1
- With diltiazem/verapamil: Use lower doses and titrate based on clinical response 1
- Avoid grapefruit juice (9-fold increase in AUC) 1
Onset of action: Inform patients that buspirone requires 2-4 weeks to become effective 4, unlike benzodiazepines which work immediately.
Clinical Pearls
- BID dosing advantages: Better compliance, simpler regimen, no difference in efficacy 2, 3
- When to use TID: Consider if patient experiences end-of-dose anxiety breakthrough with BID dosing
- Specific populations: In elderly patients with Alzheimer's-related agitation, guidelines recommend starting at 5 mg BID with maximum of 20 mg TID 4
- Abuse potential: Extremely low in general population, though isolated case reports exist in individuals with incarceration history or substance use disorder who insufflate the medication 5
The practical recommendation is BID dosing for simplicity and adherence, reserving TID dosing only for patients who demonstrate clear end-of-dose symptom breakthrough.